Fourteen modules. Twelve stages.Intelligence at every decision.

The persistent intelligence layer beneath every module across the full device lifecycle. Design history files, regulatory precedents, supplier qualifications, field performance data — all connected, all compounding. When engineering teams turn over, institutional memory stays intact. Every design decision, every V&V result, every field corrective action preserved and queryable.

Before committing to a device design, model the target patient population and use environment. Synthetic patient cohorts, disease progression models, and biomarker identification that shape design inputs and clinical study endpoints. For the KC-400 program, this module identified the closed-loop DBS opportunity and validated the AI-adaptive mechanism before a single device was built.

Continuous monitoring of the competitive and regulatory landscape throughout device development. Predicate device analysis, FDA pathway optimization, and competitor strategy detection. For neuromodulation devices, this module analyzed 23 recent PMAs to predict reviewer patterns and common deficiencies — enabling proactive preparation that compressed review timelines.

Before committing to a pivotal clinical study, simulate the design. Trial Design Optimization integrates population insights from Synthetics & Phenotype Intelligence and regulatory context from Competitive & Regulatory Intelligence to optimize the most expensive clinical decision — the pivotal trial architecture. For the ILLUMINATE trial, this module designed a sham-controlled Bayesian adaptive protocol that achieved FDA alignment.

The connective tissue between design controls and regulatory submission. Every design requirement traces to design outputs, every output traces to verification and validation tests, every test traces to acceptance criteria. Automated evidence sufficiency scoring against 510(k), PMA, CE marking, and EU MDR requirements. The difference between a clean submission and months of deficiency responses.

Continuous monitoring of supply chain vulnerabilities specific to medical devices — critical component suppliers, sterilization capacity, biocompatibility material sourcing, and contract manufacturer readiness. The difference between proactive qualification and reactive scrambling when a sole-source supplier fails an audit.

Replaces months-long market research with synthetic audiences tailored to medical device commercialization. Synthetic surgeon panels, hospital value analysis committees, GPO decision-makers, and patient panels — all calibrated to the device's specific clinical context. Test 20 value propositions in days instead of 2 in months.

Full messaging architecture grounded in the device's clinical evidence, competitive positioning, and hospital procurement reality. Value propositions, clinical differentiation, cost-effectiveness narratives — all evidence-grounded and ready for VAC presentations, surgeon education, and field sales enablement.

Models what matters to the people who decide whether hospitals can purchase your device. Hospital value analysis, GPO contracting, CMS coding and coverage, and payer evidence requirements. The bridge between clinical investment and commercial access — the difference between 42 hospitals at 6 months and 8.

In-market competitive intelligence that transforms reactive tracking into proactive strategy. Competitor device updates, FDA clearance monitoring, feature gap analysis, and market share defense. When Medtronic announces an adaptive sensing capability on Percept PC, you know the differentiation narrative before the field team hears about it.

Monitors MAUDE database, complaint management systems, manufacturing lot quality data, and clinical registries for emerging safety signals. Lot-level quality correlation identifies manufacturing process variations before they reach MAUDE thresholds. Signal classification into prioritized actions — monitor, investigate, escalate, field corrective action.

Identifies and evaluates device lifecycle extension opportunities — new indications, design refreshes, international expansion — and prioritizes them against the competitive landscape. For the KC platform, this module assessed bipolar depression expansion, KC-500 next-gen timing, and KC-Lite feasibility to maximize portfolio NPV.

When an implanted device reaches end of life, the stakes are patients depending on ongoing support. EOL timing optimization, installed base migration planning, last-time-buy strategy, and successor product transition. The difference between orderly transition and regulatory crisis when spare parts run out.

The portfolio-level view across the entire device program — tracking lifecycle position, investment allocation, and transition triggers across every product in the portfolio. Decision debt identification reveals where design reviews are overdue, where field corrective actions are deferred, and what the compounding cost of inaction is.